Janssen Research & Development, LLC
Clinical trials sponsored by Janssen Research & Development, LLC, explained in plain language.
A pharmaceutical R&D arm of Johnson & Johnson, developing drugs across multiple therapeutic areas.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Tiny trial tracks leukemia Drug's journey through the body Results expected Sep 2026 (estimated)
- Could pausing hormone therapy ease hot flashes without hurting cancer control? Results expected Oct 2026 (estimated)
- New pill aims to cut stroke risk without the bleeding worry Results expected Oct 2026 (estimated)
- New combo therapy targets tough leukemia mutations Results expected Oct 2026 (estimated)
- New hope for tough blood cancers? early trial of JNJ-89853413 begins Results expected Nov 2026 (estimated)
-
Can early symptom relief predict who stays on IBD biologic?
Disease control Not yet recruitingResearchers are tracking how long adults with moderate to severe Crohn's disease or ulcerative colitis keep taking guselkumab, a biologic drug, in routine care. The study follows about 400 people who start the treatment and records when they stop. It also checks whether early imp…
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a new injection tame severe asthma?
Disease control Not yet recruitingThis trial is testing an experimental drug called JNJ-95597528 in adults with moderate to severe asthma that is not well controlled by current treatments. The goal is to see if the drug can reduce the number of asthma attacks over 48 weeks compared to a placebo. Participants will…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New hope for myeloma patients: could ramantamig plus daratumumab outperform standard care?
Disease control Not yet recruitingThis phase 3 trial will compare a new treatment, ramantamig plus daratumumab, against two standard drug combinations for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The study aims to see if the new combo can keep the cancer from p…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC